• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » Addiction Treatment » Files

Addiction Treatment

NALOXONE Kloxxado Narcan Nasal Spray RiVive Zimhi Fact Sheet [G]

February 28, 2024

Naloxone is an opioid antagonist that is used to rapidly reverse opioid overdose. It’s important to recommend having this life-saving treatment on hand to all your patients with opioid use disorder. We recommend the generic, and now over-the-counter, nasal formulations.

Perioperative Management of Patients on Medications for Opioid Use Disorder

February 28, 2024

Medications for opioid use disorder (MOUD) can complicate pain control during and after surgery. While there are no universally adopted protocols for managing MOUD in the perioperative period, there are nonetheless helpful guidelines to consider for your patients preparing for surgery.

How to Use Motivational Interviewing in Opioid Use Disorder

February 28, 2024

Motivational interviewing (MI) is a therapeutic approach that focuses on a patient’s own motivation and commitment to change. This method is especially useful for patients who are ambivalent about quitting. With MI, therapists aim to explore these mixed feelings and highlight the patient’s reasons for wanting to get better, known as “change talk.” Helping patients resolve these mixed feelings can build a strong partnership and make it easier to create a recovery plan. MI is carried out in four steps, called Processes, each one building on the last. Here, we explain each process and offer some helpful strategies to use.

BUPRENORPHINE EXTENDED RELEASE INJECTION MONOTHERAPY Brixadi Sublocade Fact Sheet

February 28, 2024

Extended-release injectable formulations of buprenorphine allow patients to receive doses weekly, monthly, or every eight weeks for patients maintained on a low dose—which improves medication adherence. Brixadi has the advantage over Sublocade due to its more flexible dosing options.

How to Discuss and Initiate Extended Release Naltrexone Vivitrol

February 28, 2024

Extended-release naltrexone injection (XR-NTX) is an effective medication for some patients with opioid use disorder (OUD). Oral naltrexone has very weak evidence in OUD, so stick to the injectable form. It works by blocking opioid receptors, which can decrease drug cravings and prevent opioid effects if the patient does use. Because XR-NTX is an opioid blocker, patients must be opioid-free when they receive their first dose; otherwise, they could experience severe withdrawal. The need for drug abstinence before starting XR-NTX is its biggest drawback.

BUPRENORPHINENALOXONE Bunavail Suboxone Zubsolv Fact Sheet [G]

February 28, 2024

Buprenorphine/naloxone is the definitive partial agonist treatment for opioid use disorder (OUD). The combination product is preferred over buprenorphine alone for maintenance because it is the most widely available formulation and the addition of naloxone might lower its potential for misuse. The sublingual film formulation is priced a little higher than the sublingual tablets yet provides very little (if any) clinically meaningful benefit; generic tablets should be favored as a cost-saving measure.

NALTREXONE ReVia Vivitrol Fact Sheet G]

February 28, 2024

Naltrexone, an opioid antagonist, is the first-line medication for alcohol use disorder—though it is also approved for opioid use disorder (OUD). By reducing the endorphin-mediated euphoria of drinking, it helps people moderate, preventing that first drink from leading to several more. Avoid naltrexone in patients with hepatic impairment or those taking opioid-based pain medications. Methadone and buprenorphine are first-line treatments for OUD and are the best choices for most patients; however, injectable naltrexone may be an effective alternative for select patients, such as those who are highly motivated and are experiencing homelessness.

Smoking Cessation

November 29, 2023

DSM-5: “Problematic pattern” of tobacco use leading to “significant distress” that lasts at least 12 months. 1. Determine daily nicotine use. How many packs per day (20 mg nicotine is typically absorbed per 20-cigarette pack)? E-cigarettes (nicotine varies)? Chewing tobacco (one pouch = ¼ pack)? Hookah? 2. Determine the usage pattern. When does the patient have their first cigarette of the day? Does the patient smoke when sick? 3. Determine past quitting techniques. Have any worked—or not worked? From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

NICOTINE PATCH (Nicoderm, CQ, others) Fact Sheet [G]

November 29, 2023

Nicotine patches are a first-line intervention in patients who are able to quit smoking at initiation of treatment and who are regular and constant smokers. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

ACAMPROSATE (Campral) Fact Sheet [G]

November 29, 2023

Acamprosate is best for maintaining abstinence in patients who have already quit, but it can be helpful even after patients relapse. Naltrexone is the better choice for patients who are still drinking, since it is better at helping patients quit. Acamprosate is also preferred over naltrexone in patients with hepatic impairment. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

Previous 1 2 3 4 5 6 7 8 9 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.